(Opicinumab)Biosimilar Reference Antibody-GS40509 新品

货号：GS40509

Opicinumab (also known as BIIB‑033 or anti‑LINGO‑1) is a fully human monoclonal antibody that targets leucine‑rich repeat and immunoglobulin‑like domain‑containing protein 1 (LINGO‑1), a transmembrane glycoprotein expressed primarily in the central nervous system (CNS) on neurons and oligodendrocytes. LINGO‑1 is a negative regulator of oligodendrocyte differentiation, myelination, and axonal regeneration. By binding to and inhibiting LINGO‑1, opicinumab aims to promote remyelination and axonal repair in demyelinating diseases. It has been clinically evaluated as a remyelination and neuroprotective therapy for multiple sclerosis (MS), including relapsing and progressive forms, but has not yet demonstrated conclusive efficacy in Phase II trials.